The "Summary Page" provides a listing of drug names and safety labeling sections revised: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm181141.htm
Clicking on a drug product name in the Summary View will take you to the "detailed view" page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information to the BOXED WARNING, CONTRAINDICATIONS, and/or WARNINGS sections.
The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS, and WARNINGS sections:
DexFerrum (iron dextran), INFeD (iron dextran), Tasigna (nilotinib), Arixtra (fondaparinux sodium), Flagyl (metronidazole), Inomax (nitric oxide), Lariam (mefloquine hydrochloride), Letairis (ambrisentan), Lopressor HCT (metoprolol tartrate and hydrochlorothiazide), Merrem (meropenem), Primaxin (imipenem and cilastatin), Pristiq (desvenlafaxine), Tobramycin, Zoladex (goserelin acetate).
Clicking on a drug product name in the Summary View will take you to the "detailed view" page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information to the BOXED WARNING, CONTRAINDICATIONS, and/or WARNINGS sections.
The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS, and WARNINGS sections:
DexFerrum (iron dextran), INFeD (iron dextran), Tasigna (nilotinib), Arixtra (fondaparinux sodium), Flagyl (metronidazole), Inomax (nitric oxide), Lariam (mefloquine hydrochloride), Letairis (ambrisentan), Lopressor HCT (metoprolol tartrate and hydrochlorothiazide), Merrem (meropenem), Primaxin (imipenem and cilastatin), Pristiq (desvenlafaxine), Tobramycin, Zoladex (goserelin acetate).
